|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0185117,
umls-concept:C0205420,
umls-concept:C0332293,
umls-concept:C0600558,
umls-concept:C0684249,
umls-concept:C1333355,
umls-concept:C1514162,
umls-concept:C1514475,
umls-concept:C1516213,
umls-concept:C2911684
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2008-9-15
|
|
pubmed:abstractText |
Excision repair cross-complementation Group 1 (ERCC1) overexpression is associated with resistance to cisplatin-based chemotherapy in patients with nonsmall-cell lung cancer (NSCLC). A preliminary study also suggested that ERCC1 expression is associated with radioresistance in lung cancer cells. The aim of this study was to evaluate the clinical implications of ERCC1 expression in stage IIIA N2-positive NSCLC patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
(c) 2008 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
113
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1379-86
|
|
pubmed:meshHeading |
pubmed-meshheading:18623378-Adenocarcinoma,
pubmed-meshheading:18623378-Adult,
pubmed-meshheading:18623378-Aged,
pubmed-meshheading:18623378-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18623378-Carboplatin,
pubmed-meshheading:18623378-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:18623378-Chemotherapy, Adjuvant,
pubmed-meshheading:18623378-Cisplatin,
pubmed-meshheading:18623378-Combined Modality Therapy,
pubmed-meshheading:18623378-DNA-Binding Proteins,
pubmed-meshheading:18623378-Disease-Free Survival,
pubmed-meshheading:18623378-Endonucleases,
pubmed-meshheading:18623378-Etoposide,
pubmed-meshheading:18623378-Female,
pubmed-meshheading:18623378-Humans,
pubmed-meshheading:18623378-Immunoenzyme Techniques,
pubmed-meshheading:18623378-Lung Neoplasms,
pubmed-meshheading:18623378-Male,
pubmed-meshheading:18623378-Middle Aged,
pubmed-meshheading:18623378-Neoadjuvant Therapy,
pubmed-meshheading:18623378-Neoplasm Staging,
pubmed-meshheading:18623378-Paclitaxel,
pubmed-meshheading:18623378-Survival Rate,
pubmed-meshheading:18623378-Taxoids,
pubmed-meshheading:18623378-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
|
|
pubmed:affiliation |
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
|
|
pubmed:publicationType |
Journal Article
|
